Alkaloids from Lime Flower (Tiliae flos) Exert Spasmodic Activity on Murine Airway Smooth Muscle Involving Acetylcholinesterase

Authors
Alexander Hake1,2, Nico Symma2, Stefan Esch2, Andreas Hensel2, Martina Düfer1,2

Affiliations
1 Institute of Pharmaceutical and Medicinal Chemistry, Department of Pharmacology, University of Münster, Münster, Germany
2 Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Münster, Germany

Key words
Tilia platyphyllos, Tilia cordata, Malvaceae, alkaloids, acetylcholinesterase inhibitor, tracheal smooth muscle

ABSTRACT
Lime flower (Tiliae flos) is traditionally used either for treatment of the common cold or to relieve symptoms of mental stress. Recently, the presence of a new class of piperidine and dihydro-pyrrole alkaloids from lime flower has been described. The present study aimed to investigate the pharmacological activity of hydroacetonic lime flower extracts, alkaloid-enriched lime flower fractions, and isolated alkaloids on the murine airway smooth muscle and the cholinergic system. While a hydroacetonic lime flower extract did not show any pharmacological activity, enriched Tilia alkaloid fractions potentiated acetylcholine-induced contractions of the trachea by ~ 30%, showing characteristics comparable to galanthamine. Effects were abrogated by atropine, indicating an involvement of muscarinic receptors. The dihydro-pyrrole alkaloid tiliine A, the piperidine alkaloid tiliamine B, and the acetylated piperidine alkaloid tilacetine A were characterized as acetylcholinesterase inhibitors. The positive control galanthamine (IC50 = 2.0 µM, 95% CI 1.7 to 2.2 µM) was approximately 100 times more potent compared to tiliine A (IC50 = 237 µM, 95% CI 207 to 258 µM) and tiliamine B (IC50 = 172 µM, 95% CI 158 to 187 µM). Neither DNA synthesis of HepG2 liver cells, HaCaT keratinocytes, and Caco-2 intestinal epithelial cells nor cell viability of primary human fibroblasts was reduced by the alkaloids. The indirect cholinergic activity of the alkaloids might explain some aspects of the traditional use of lime flowers and may extend the portfolio of compounds with regard to diseases involving parasympathetic malfunction or central cholinergic imbalance.

Introduction
Since the Middle Ages, aqueous extracts from lime flower (Tiliae flos) have been used in Europe for treatment of the common cold due to diaphoretic properties [1]. The European Pharmacopoeia describes the flowers, including the bracts, from Tilia cordata MILL., Tilia platyphyllos SCOP., and Tilia vulgaris HEYNE (syn. Tilia europaea), a hybrid of both, Malvaceae, as well as their mixtures as raw materials for use as a herbal medicinal product [2]. Therapeutic use of lime flower preparations is specified by the Committee on Herbal Medicinal Products (HMPC) of the European Medi-
cines Agency (EMA) for treatment of common cold symptoms as well as for relieving symptoms of mental stress [1]. Pharmacological data suggest that fractions from *Tilia tomentosa* show anxiolytic and sedative properties, which has been proven by plus-maze and hole-board tests [3]. Moreover, an extract from *T. europaea* inhibited muscimol binding in a specific binding assay and increased the $^{36}$Cl$^-$ uptake in synaptoneurosomes, indicating a direct interaction with the GABA$_A$ receptor [4]. This effect might be caused by GABA [4] or by $\beta$-sitosterol and fatty acids, which were identified as the active compounds in *T. americana* [5]. In agreement with this, an orally administered extract from *T. europaea* exerted anxiolytic properties in mice [6]. In contrast, data addressing potential beneficial effects of lime flower preparations on symptoms of the common cold are heterogeneous and the mechanisms have not been adequately investigated until now. In folk medicine, diaphoresis has been strongly associated with a decrease in fever as a result of sweating, while an antispasmodic effect is assessed to be beneficial for curing cough symptoms [1]. Diaphoretic compounds in lime flower preparations have been suggested to be quercetin, kaempferol, and $p$-coumaric acid [1], but due to the limited bioavailability of quercetin and its glycosides after oral intake [7], and the wide distribution of these compounds in many other plants, it is rather unlikely that they indeed contribute to the claimed diaphoretic effects. Only limited information is available on the potential effects of *Tilia* extracts and isolated compounds concerning antispasmodic activity on the level of isolated tissue or whole organs. An antispasmodic effect on 5-HT-induced contractions on the rat ileum has been proven for an aqueous extract from *T. europaea*, while noradrenaline-induced contractions in the guinea pig aorta have not been abrogated [8]. The same extract neither affected ACh- nor histamine-induced contractions on the guinea pig ileum, but induced contractions that could be abolished by atropine [8]. Interestingly, the spasmodic, but not the antispasmodic effect, could be confirmed for dispersed intestinal smooth muscle cells by using an ethanolic extract from *T. cordata* [9]. Similar to the results described for ileal tissue, effects were antagonized by atropine [9]. Finally, it is discussed that polysaccharides as part of lime flower could reduce cough via bioadhesive layers on mucous membranes [10]. Due to the fact that *in vitro* experiments have shown contrary effects on smooth muscle without identifying any compounds responsible for spasmodyc and antispasmodic effects and as adequate investigations on the lower respiratory tract are missing until now, the antispasmodic effect can be hardly transferred to treatment for cough.

The phytochemical composition of lime flower has been exhaustively investigated. Pharmaceutically relevant compounds are polysaccharides, predominantly acidic arabinogalactans [11]. Flavonoids, especially glycosides of kaempferol (e.g., astragalin, tiliroside) and quercetin (e.g., isoquercitrin, rutin, hyperoside), have been described, as already mentioned above [12–14]. Furthermore, volatile oil, containing monoterpenes (e.g., linalool, geraniol, 1,8-cineole) and phenylpropanes (e.g., eugenol, anethol, 2-phenylethanol), contributes to the aromatic taste of lime flower extracts [14]. Other natural products in lime flower are oligomeric proanthocyanidins, mainly composed of catechin and epicatechin [15, 16]. Additionally, organic acids (e.g., $p$-coumaric acid, caffeic acid), tocopherol, carbohydrates, saponins, amino acids, and hydroxylated coumarins can be found [1]. Recently, our group identified three series of each two diastereomeric alkaloids in hydroacetic extracts of lime flower, namely, two 2-methyl-3,4-dihydro-2H-pyrrol-3-ols (tililine A and B), two 2-methyl-piperidin-3-ols (tililamine A and B), and two 3-O-acetylated 2-methyl-piperidin-3-ol alkaloids (tilacetine A and B) [17]. Structural features of these unusual alkaloids are displayed in *Fig. 1*. Quantitative investigations revealed the presence of these alkaloids in hydroalcoholic extracts and in aqueous lime flower infusions also [17].

The present study investigated the potential pharmacological activity of *Tilia* extracts, enriched *Tilia* alkaloid fractions, and the isolated alkaloids. Pharmacological investigations were performed on isolated mouse tracheal slices by an AChE activity assay. In addition, *in vitro* toxicity regarding DNA synthesis of different cell lines was tested by BrdU incorporation assays and metabolic activity by MTT turnover.

**Results**

Lime flower herbal material was extracted with acetone/water (7:3 v/v) and alkaloids were isolated and characterized as described in detail by Symma et al. [17]. After removal of the organic solvent, the aqueous solution was extracted with petroleum ether for removal of lipophilic compounds. The extract (TE) was fractionated by use of a cationic exchanger, yielding a basic fraction TF$_1$, which was subsequently fractionated on Sephadex LH-20 [17]. This resulted in an alkaloid containing fraction TF$_2$, which was subsequently purified in order to remove disturbing substances (e.g., the flavonoid linarin) by preparative HPLC on an RP18 stationary phase [17]. Thereby, the enriched *Tilia* alkaloid fraction TF$_3$ was fractionated and the purified alkaloids 1a, 2b, and 3a were isolated and quantified [17]. The fractionation scheme is displayed in *Fig. 15*, Supporting Information.

TE was characterized by LC-(+)ESI-qTOF-MS and peaks were assigned to known components of the genus *Tilia* by interpretation of MS$_2$ and UV spectra (*Table 1* and *Fig. 2c*). The alkaloid containing fractions TF$_2$ and TF$_3$ were analyzed by HPLC-MS, indicating the presence of six different alkaloids, which had been identified as the dihydro-pyrrol alkaloid 1a (tililine A), the piperidine alkaloid 2b (tililamine B), and the acetylated piperidine alkaloid 3a (tilacetine A) and their corresponding diastereomeric forms (*Figs. 3e* and *4d*). As described by Symma et al. [17], all *Tilia* alkaloids of this fraction occur in two different diastereomeric forms, which are both cis-configurated at the positions 2 and 3 of the heterocycle. Until now, it is still unclear which absolute configuration can be attributed to which compound. For pharmacological tests, the alkaloids, which had been isolated in the highest amounts, were used, namely, tililine A (1a), tililamine B (2b), and tilacetine A (3a). The other diastereomers could not be tested due to low yields during isolation. Using a calibrated HPLC-MS method, the content of the alkaloids in the extract TE was determined as follows: 1a 1.7 mg/g dry weight of the extract, 2b <0.1 mg/g, and 3a 0.9 mg/g.

For investigation of potential effects of the TE and the alkaloids, the mouse trachea was used as a model for the lower respiratory tract. The tissue bath experiments were performed with...
the TE and enriched *Tilia* alkaloid fractions TF2 and TF3 containing tiliine A (1a), tiliamine B (2b), and tilacetine A (3a) (Figs. 2–4). Even though it is possible to detect the alkaloids in the TE using a calibrated HPLC-MS method (1 mg/mL TE contains approximately 5 µM tiliine A and B, 4 µM tilacetine A and B, and less than 1 µM tiliamine A and B, calculations were based on the HPLC-ESI-qTOF data reported in [17]), a 10-min pretreatment of isolated tracheal slices with 1 mg/mL TE did not affect the contraction maximum induced by 100 µM ACh in the continued presence of TE (Fig. 2a, b: contraction force TE + ACh 88 ± 16%, related to the control with ACh, which was set to 100%; p > 0.05).

On the contrary, the enriched *Tilia* alkaloid fractions TF2 and TF3 significantly increased the ACh-induced contractions (Figs. 3 and 4). After a 10-min pretreatment of the mouse trachea slices with 1 mg/mL TF2, ACh (100 µM) caused a significantly higher contraction compared to control experiments (Fig. 3a, b: contraction force TF2 + ACh: 129 ± 8% compared to the control ACh alone: 100%; p < 0.05). Of note, an increase in the basal tone was observed during the pretreatment period. As this affected the contraction maximum, experiments were reevaluated after subtraction of the change in basal tone (contraction force TF2 + ACh after subtraction of the alteration in basal tone: 114 ± 2%; p < 0.001 compared to ACh alone). In another series of experiments, TF2 (1 mg/mL) was added to the precontracted tracheal slices 5 min after application of ACh (100 µM). In this setup, the maximum force induced by ACh was acutely elevated. (Fig. 3c, d: contraction force TF2, minute 9–10, after adding ACh: 128 ± 6%, related to the contraction force in minute 4–5 after adding ACh). For the control, the time course of ACh-induced contractions without the addition of TF2 was analyzed in analogy (contraction force of the control minute 9–10 after adding ACh: 103.7 ± 0.2%, related to the contraction force in minute 4–5 after adding ACh; p < 0.05 vs. TF2-induced change). Reversibility was proven by application of ACh after washout of the test compound. The purity of TF2 was determined by UHPLC-DAD and the concentrations of alkaloids were roughly estimated from the chromatograms. In total, the alkaloids accounted for 18.3% of the peak area and, based on the single peak values, the concentrations of the diastereomers in 1 mg/mL TF2 amounted to 35 µM tiliine A/B, 245 µM tiliamine A/B, and 71 µM tilacetine A/B. In order to investigate if the magnitude of the effect depends on the degree of ACh-induced concentrations, the tracheal slices were pretreated 10 min with a further purified alkaloid-enriched fraction (TF3) of the TE, and ACh was added in a cumulative manner (1–200 µM) in the presence of this fraction (Fig. 4a). A contraction power induced by 200 µM ACh was set as a 100% control. In these experiments, the purified fraction TF3 was chosen to make sure that the effect was not mediated by trace amounts of other compounds (e.g., linarin) found in TF2 (Fig. 3e, peak "L"). The concentration of the respective alkaloids in 0.1 mg/mL TF3 (calculated by UHPLC-DAD) was 26 µM for tiliine A/B, 73 µM for tiliamine A/B, and 17 µM for tilacetine A/B. With this fraction (0.1 mg/mL),
<table>
<thead>
<tr>
<th>Peak No</th>
<th>tR [min]</th>
<th>λmax [nm]</th>
<th>Error [mDa]</th>
<th>mΣ</th>
<th>MS² fragments (m/z)</th>
<th>Ion formula</th>
<th>Tentative compound identity</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.313</td>
<td>280</td>
<td>47.0</td>
<td>4.6</td>
<td>409.0897, 287.0542, 163.0346, 127.0379</td>
<td>[C30H27O12]+</td>
<td>procyanidin B-type dimer</td>
<td>J, K, S, Z</td>
</tr>
<tr>
<td>2</td>
<td>1.584</td>
<td>280</td>
<td>2.6</td>
<td>0.6</td>
<td>139.0358, 123.0424</td>
<td>[C15H15O6]+</td>
<td>(epi)catechin</td>
<td>J, K, Z</td>
</tr>
<tr>
<td>3</td>
<td>2.672</td>
<td>268, 352</td>
<td>3.2</td>
<td>3.7</td>
<td>303.0482</td>
<td>[C27H31O16]+</td>
<td>quercetin-hexoside-deoxyhexoside</td>
<td>J, K, S, Z</td>
</tr>
<tr>
<td>5</td>
<td>3.851</td>
<td>270</td>
<td>2.5</td>
<td>1.4</td>
<td>348.2523, 330.2414, 224.2039</td>
<td>[C32H44NO8]+</td>
<td>tiliine A</td>
<td>SY</td>
</tr>
<tr>
<td>6</td>
<td>4.048</td>
<td>270</td>
<td>2.3</td>
<td>3.8</td>
<td>*</td>
<td>[C32H44NO8]+</td>
<td>tiliine B</td>
<td>SY</td>
</tr>
<tr>
<td>7</td>
<td>4.253</td>
<td>280, 350</td>
<td>3.0</td>
<td>3.5</td>
<td>303.0491</td>
<td>[C20H19O11]+</td>
<td>quercetin-pentoside</td>
<td>J, S</td>
</tr>
<tr>
<td>9</td>
<td>5.126</td>
<td>280, 346</td>
<td>1.6</td>
<td>3.1</td>
<td>303.0491</td>
<td>[C21H19O13]+</td>
<td>quercetin-glucuronide</td>
<td>Z</td>
</tr>
<tr>
<td>10</td>
<td>5.806</td>
<td>276</td>
<td>0.4</td>
<td>9.0</td>
<td>494.3117, 350.2700, 332.2570, 208.2080</td>
<td>[C32H46NO8]+</td>
<td>tillamine B</td>
<td>SY</td>
</tr>
<tr>
<td>11</td>
<td>5.880</td>
<td>272, 352</td>
<td>1.5</td>
<td>3.3</td>
<td>303.0486</td>
<td>[C21H21O11]+</td>
<td>quercetin-hexoside</td>
<td>J, K, S, Z</td>
</tr>
<tr>
<td>12</td>
<td>6.135</td>
<td>280</td>
<td>0.2</td>
<td>1.2</td>
<td>492.2955, 390.2638, 330.2432</td>
<td>[C29H46NO8]+</td>
<td>acetylated tiliine</td>
<td>SY</td>
</tr>
<tr>
<td>14</td>
<td>7.126</td>
<td>280</td>
<td>0.1</td>
<td>0.6</td>
<td>494.3114, 392.2801, 332.2586, 208.2049</td>
<td>[C29H46NO8]+</td>
<td>talacetine A</td>
<td>SY</td>
</tr>
<tr>
<td>15</td>
<td>7.365</td>
<td>280</td>
<td>1.1</td>
<td>4.6</td>
<td>494.3110, 392.2788, 332.2580, 208.2066</td>
<td>[C29H46NO8]+</td>
<td>talacetine B</td>
<td>SY</td>
</tr>
<tr>
<td>16</td>
<td>8.083</td>
<td>280, 316</td>
<td>0.4</td>
<td>51.7</td>
<td>447.1285, 285.0749</td>
<td>[C32H31O16]+</td>
<td>acacetin-hexoside-deoxyhexoside (linarin)</td>
<td>F, Z</td>
</tr>
<tr>
<td>17</td>
<td>8.539</td>
<td>276, 310, 348</td>
<td>2.3</td>
<td>11.6</td>
<td>287.0540, 147.0413</td>
<td>[C30H32O13]+</td>
<td>tiliroside</td>
<td>J, K, Z</td>
</tr>
</tbody>
</table>

*Precursor ion with too less intensity; References: J: [34], K: [12], SY: [17], S: [35], Z: [36]
no effect on the basal tone was observed during the pretreatment period (Table 2). TF3 exhibited significantly stronger contractile responses compared to the control (Fig. 4c): contraction force TF3 + ACh 10 µM: 52 ± 5% of the contraction obtained with 200 µM ACh vs. control ACh 10 µM: 38 ± 1%; p < 0.05; contraction force TF3 + 100 µM ACh: 103 ± 6% vs. control ACh 100 µM: 80 ± 3%; p < 0.001). Up to now, our data clearly indicates that the alkaloid-enriched fractions of TE potentiate the effect of ACh. Galanthamine, a known inhibitor of AChE [18], was tested in the same manner in a concentration of 0.5 µM (Fig. 4b). This concentration was chosen because it did not significantly affect the basal tone (Table 2). As expected, the AChE inhibitor potentiated the contractions induced by the exogenous application of ACh (Fig. 4b,c). In the presence of atropine (1 µM), all effects were abrogated and neither TF3 and galanthamine nor ACh led to any contractile response, as illustrated in representative example measurements (Fig. 4a,b).

To investigate whether AChE is a molecular target of the Tilia alkaloids, the three compounds 1a (tiline A), 2b (tiliamine B), and 3a (tilacetine A) were tested for a potential influence on the AChE of Electrophorus electricus. The results indicate that the alkaloids 1a and 2b are inhibitors of AChE (1a: IC50 = 237 µM, 95% CI 207 to 258 µM, 2b: IC50 = 172 µM, 95% CI 158 to 187 µM), while the 3-O-acetylated tilacetine A was much less effective (900 µM, 3a: 45 ± 2% inhibition) (Fig. 5a). Galanthamine was approximately 100 times more potent compared to 1a and 2b (IC50 = 2.0 µM, 95% CI 1.7 to 2.2 µM).

The effect of the test compounds 1a, 2b, and 3a on DNA synthesis of three cell lines, human liver cells (HepG2), human nontumorigenic keratinocytes (HaCaT), and human intestinal epithelial cells (Caco-2), was tested by a BrdU ELISA in order to investigate potential cell toxicity [19]. As displayed in Table 3, DNA synthesis of the alkaloid-treated cells (1–100 µM, 24 h) was not significantly different to the respective untreated control groups, indicating the absence of antiproliferative toxic effects against the selected cell lines. In addition, Tilia alkaloids did not decrease metabolic activity, determined by a colorimetric MTT assay in primary human fibroblasts (Fig. 5b). While tilacetine A turned out to slightly increase MTT turnover at a concentration of 100 µM, all other compounds did not significantly affect cell metabolism in both directions.

Hake A et al. Alkaloids from Lime... Planta Med | © 2021. Thieme. All rights reserved.
Discussion

The traditional use of *Tiliae flos* for the treatment of cough suggests relaxing effects on airway smooth muscle. Surprisingly, the TE turned out to have neither antispasmodic nor spasmolytic activities on murine airway smooth muscle (Fig. 2a, b). Therefore, our findings provide no scientific evidence for using lime flower to treat cold symptoms via relaxation of the smooth muscle of the lower respiratory tract. On the contrary, the present study revealed that the fractions TF2 and TF3 contain spasmodic compounds, as both fractions potentiated the ACh-induced contractions (Fig. 3a, b and 4a, c). The scatterplots show the mean contraction force of three independent experiments in % ± SD (related to the control contractions) and the single measured values. e UV chromatogram of fraction TF2 at λ = 280 nm with marked peaks of tested compounds tiliine A (1a), tiliamine B (2b), and tilacetine A (3a). Peaks marked with a or b symbolize diastereomers of the respective *Tilia* alkaloids, as proven by the m/z values. The peak labeled with "L" is supposed to be linarin, based on the MS data (*p < 0.05).

... was processed...
The inhibition would be around 40%. The effect on the basal tone observed in response to 1 mg/mL TF3 is in agreement with reports for galanthamine [22] and might result from a reduced degradation of endogenous ACh release within the organ sample. However, we cannot exclude other targets that are addressed by the newly characterized alkaloids, e.g., improved receptor sensitivity to ACh or effects on intracellular signaling pathways. Interestingly, our data show that the acetylation of the 3-hydroxy-substituted piperidine ring decreased the inhibition potency, suggesting that the piperidine heterocycle of the molecule seems to be the func-

Table 2 Influence of TF3 and galanthamine (0.5 and 1 µM) on the basal tone.

<table>
<thead>
<tr>
<th>Contraction force (%)</th>
<th>Control</th>
<th>TF3 (0.1 mg/mL)</th>
<th>Galanthamine (0.5 µM)</th>
<th>Galanthamine (1 µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>−1 ± 1</td>
<td>0 ± 1</td>
<td>5 ± 10</td>
<td>21 ± 18**,*#,#,§</td>
<td></td>
</tr>
</tbody>
</table>

The data listed in the table represents the mean contraction force in % ± SD of three (TF3) and five (galanthamine 0.5 and 1 µM) independent experiments and the respective controls (n = 13). Data was normalized to the effect of ACh (200 µM) in the absence of test compounds. **P < 0.01 vs. control, ***P < 0.001 vs. control, *P < 0.05 vs. control, #P < 0.01 vs. TF3 0.1 mg/mL, §P < 0.05 vs. TF3 0.1 mg/mL.
tional group responsible for targeting AChE. This hypothesis might be supported by data reported for other piperidine-containing compounds. Hydroxy-methyl-substituted alkyl-piperidine alkaloids from *Senna spectabilis* have been shown to be AChE inhibitors [23]. Furthermore, the piperidine alkaloid juliflorine has also been described as a potent inhibitor of AChE [24]. To the best of our knowledge, this is the first time that an AChE inhibition is reported for 2-methyl-3,4-dihydro-2H-pyrrol-3-ol derivatives.

The impact of the glycosylation of the alkaloids remains unclear at the present stage. Future experiments should clarify if glycosylation influences the permeation over barrier membranes and if the sugar moiety influences the AChE inhibitory activity. No negative influence of the test compounds has been observed against HepG2, HaCaT, and Caco-2 cell lines with respect to BrdU incorporation. This might be a promising hint, especially concerning liver cells, as, e.g., tacrine, the prototype of AChE inhibitors for treating Alzheimer’s disease, was withdrawn from the market due to pronounced liver toxicity [25]. The MTT assay with primary human fibroblasts further supports that the alkaloids do not impair cell function or viability. The reason for the significantly higher level of MTT turnover observed with 100 µM tilacetine A is unclear. As it was not concentration dependent, it most likely results from incidental variations in the cell population and not from targeted induction of cell proliferation. For lime flower, no toxicity studies have been published, until now, and the herbal medicinal material is generally regarded as nontoxic.

The results reported are interesting in respect to two aspects. First, the AChE inhibition and the subsequent activation of muscarinic signaling pathways by the alkaloids can contribute to the understanding of the traditional use of lime flower extracts as a diaphoretic agent. Local inhibition of AChE was reported to increase the sweat rate in human volunteers [26], and hyperhidrosis was described for licensed AChE inhibitors [27]. Not only *Tilia* extracts, but also herbal teas contain *Tilia* alkaloids [17]. Proposed sudatory infusions include two cups of lime flower tea (4 g of herbal material per cup) [1], resulting in an intake of approximately 1.5 mg of *Tilia* alkaloids. Dependent on their pharmacokinetic properties, the alkaloids might contribute to diaphoresis to-

![Fig. 5](image)

**Fig. 5** a Inhibitory influence of *Tilia* alkaloids on AChE. The values represent the mean inhibition (% ± SD) of the AChE by different test compounds as indicated in the diagram. Samples were measured in triplicate. b Effect of *Tilia* alkaloids on metabolic activity of primary human fibroblasts. MTT reduction was determined after incubation with the indicated concentrations of the *Tilia* alkaloids for 24 h. The scatterplot illustrates the mean ± SD of four independent experiments and the single data points; **p < 0.01 vs. control.

### Table 3

<table>
<thead>
<tr>
<th></th>
<th>HepG2 (%)</th>
<th>HaCaT (%)</th>
<th>Caco-2 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100 µM</td>
<td>10 µM</td>
<td>1 µM</td>
</tr>
<tr>
<td>Tiliine A (1a)</td>
<td>94 ± 9</td>
<td>93 ± 9</td>
<td>91 ± 7</td>
</tr>
<tr>
<td>Tiliamine B (2b)</td>
<td>97 ± 10</td>
<td>91 ± 5</td>
<td>92 ± 12</td>
</tr>
<tr>
<td>Tilacetine A (3a)</td>
<td>94 ± 6</td>
<td>94 ± 8</td>
<td>94 ± 6</td>
</tr>
<tr>
<td>DMSO 10%</td>
<td>27.6 ± 0.5</td>
<td>45 ± 6</td>
<td>32 ± 2</td>
</tr>
</tbody>
</table>

The values represent the mean ± SD from three independent experiments with two to three technical replicates (one independent experiment with two to three technical replicates). Test groups with supplementation of DMSO served as a positive control. **p < 0.01 vs. control.
gether with heat-induced effects. Secondly, one can consider a chance for new indication areas for formulations with standardized and sufficiently high alkaloid content. Peripheral reduction of AChE activity was suggested for treatment of urinary retention or myasthenia gravis [28, 29]. In case of sufficient delivery across the blood-brain barrier, the alkaloids might extend the spectrum of drugs used for therapy of central dysfunction of the cholinergic system, e.g., early stages of Alzheimer’s disease or other forms of cognitive decline.

Future experiments should focus on intestinal absorption, metabolism, and the ability of the compounds to cross the blood-brain barrier. There is evidence that the alkaloids found in lime flower can function as hydrophilic prodrugs due to their phenol-glycoside moiety being absorbed via the duodenal Na+/glucose carrier [30]. These glycosides might be subsequently activated by deglycosylation, as has been reported for arbutin, for which the pharmacokinetics is already characterized [31].

In summary, the present study reveals the pharmacological activity of the *Tilia* alkaloids on AChE and mouse trachea. The traditional use of lime flower might comprise such mechanisms. In addition, our findings provide new perspectives for the potential benefit of lime flower preparations with a standardized alkaloid content.

**Materials and Methods**

**Plant material – extraction and isolation**

Lime flower plant material was collected on June 16 and July 2, 2019, at the Medicinal Plant Botanical Garden of the University of Münster (Germany, 51°57′54.5″N 7°36′24.4″E) and identified as *T. platyphyllos* SCOP. and *T. cordata* MILL. by A.H. and N.S. Voucher specimens (IPBP 512, IPBP 513) are deposited at the archives of the Institute of Pharmaceutical Biology and Phytochemistry (Münster, Germany). As described in Symma et al. [17] in detail, the dried and cut herbal mixture of *T. platyphyllos* and *T. cordata* (1.3 kg) was extracted in aliquots of 100 g (2 × 1000 mL) with a mixture of cold acetone/water (7 : 3 v/v) (Fig. 1S, Supporting Information). After removal of acetone under vacuum, the aqueous phase was extracted with petroleum ether (5 × 600 mL for each extraction step) to remove lipophilic compounds, resulting in 225 g (17% w/w, related to the starting material) of TE. The isolation of *Tilia* alkaloids was carried out by different fractionation steps using cationic exchange Sephadex LH-20 chromatography and preparative HPLC on an RP18 stationary phase as reported in Symma et al. [17]. Six alkaloids have been isolated and identified, representing three pairs of diastereomers. The absolute stereochemistry has not been identified yet [17]. The diastereomers tested were tiline A (1a), tilamine B (2b), and tilacetine A (3a).

**Chemicals, reagents, cell lines**

All solvents were of analytical quality and obtained from VWR International. ACh chloride (purity > 99%) was purchased from Sigma-Aldrich. Atropine (purity > 99%) was obtained from TCI Chemicals. Galanthamine (purity > 99%) was kindly provided by Jansen-Cilag. Cell lines used: HepG2 (ATCC HB-8065, clone H20) was obtained from Prof. Mersch-Sundermann, Freiburg, Germany, HaCaT (ATCC CCL-17) was a friendly gift from Prof. Fusenig, Heidelberg, Germany to A.H., and CaCo-2 cells (ATCC HTB-37, ACC 169) were kindly provided by Prof. Langer, Münster, Germany. Primary human normal dermal fibroblasts were resected from human foreskins, which were kindly provided by the University Hospital of Münster, Germany.

**Animals and preparation of mouse tracheal slices**

Male and female C57BL/6 N mice [Charles River and own breeding (Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Germany)] were housed under standard conditions. Animal care followed the rules of German laws (Az. 53.5.32.7.1/ MS-12668, December, 4, 2018, Health and Veterinary Office Münster, Germany). The mice were sacrificed using CO2. After removing surrounding tissue, the trachea was excised, cut into 3 mm slices, and stored in Krebs-Henseleit buffer at 4 to 8 °C until the experiments started.

**Tissue bath experiments**

Experiments were performed by the use of 3 mm tracheal slices in a Mayflower Horizontal Tissue Bath (Hugo Sachs Elektronik). Tracheal slices were placed between the hooks of the 5‐mL tissue bath chamber containing Krebs-Henseleit buffer (in mM: NaCl 118.1, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose 5.6, pH of 7.4, and temperature of 37°C). Each slice was adjusted to a preload of 0.2 N. After an equilibration time of 60 min, the experiments were started. During the experiment, the buffer was constantly gassed with carbogen (95%:O2; 5%:CO2). The contraction force was measured isometrically every 2 s by using a force transducer (F10 Type 375), an amplifier (TAM-A Type 705/1), and evaluation software (HSE ACAD 2.0). Contraction induced by ACh reached a steady state within 5 min. In the experiments with 100 µM ACh, the last contraction of the three succeeding contraction controls was used as the 100% control and test solutions were added 10 min before and during the next 5-minute bolus of ACh. When the effect on top of the contraction maximum of 100 µM ACh was investigated, the last contraction before the addition of the test compound was used as a control, the contraction in minute 4–5 after adding ACh was set to 100%, and substances (treatment time of 5 min) and controls were evaluated in minute 9–10 after the addition of ACh. In the experiments in which ACh was added in a cumulative manner (every 5 min), the averaged data of the last three ACh-induced control contractions were taken as a control and the contraction force at a concentration of 200 µM ACh was set as 100%. Test compounds were present 10 min before and during the stepwise elevation of ACh.

**Phytochemical characterization of *Tilia* extract**

UHPLC-ESI-qTOF-MS analysis was performed using a Dionex Ultimate 3000 RS Liquid Chromatography System with a Waters Acquity UPLC BEH C18 (2.1 × 100 mm, 1.7 µm) column at a temperature of 40°C. The injection volume was 10 µL and the flow rate was 0.4 mL/min. Samples were dissolved in methanol/water (1 : 9 v/v) at a concentration of 10 mg/mL. The binary gradient was comprised of (A) water with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid. Gradient t0: 0.00 to 9.00 min linear
from 15% B initially to 38% B; 9.00 to 9.02 min linear from 38 to 100% B; 9.02 to 15.00 min isocratic at 100% B; 15.00 to 15.10 min linear from 100 to 15% B; 15.10 to 20.00 min isocratic equilibration at 15% B. Eluted compounds were detected using a Dionex Ultimate DAD-3000 RS over a wavelength range of \( \lambda = 200 \) to 400 nm and a Bruker Daltonics microTOF-QII time-of-flight mass spectrometer equipped with an Apollo electrospray ionization source in the positive mode at 3 Hz over a mass range of \( m/z \) 50–1500 using the following instrument settings: nebulizer gas nitrogen: 3.0 bar; dry gas nitrogen: 9 L/min, 200°C; capillary voltage: 4500 V; end plate offset: 500 V; transfer time: 100 µs, prepulse storage: 6 µs, collision energy: 8 eV. MS/MS scans were triggered by AutoMS2 settings within a range of a collision energy of 40 eV and collision cell RF of 130 Vpp. The UV chromatogram at 280 nm and the base peak chromatogram of TE are displayed in Fig. 2c. The major peaks of the base peak chromatogram were identified by comparison of the \( m/z \) values from the \([M + H]^+\) ion and the respective MS2 spectra with the respective data sets from the literature (Table 1).

**UHPLC-PDA analysis**

Fractions TF2 and TF3 were analyzed via a Waters Acquity UPLC system on an Acquity UPLC HSS T3 (1.8 µm, 2.1 × 100 mm) stationary phase (Waters). Mobile phase: (A) water with formic acid 0.1%; (B) acetonitrile with 0.1% formic acid. The gradient was designed as follows: \( t_g \) 0 to 4 min: linear from 0 to 18% B; 4 to 14 min: 18 to 30% B; 14 to 16 min: 30 to 100% B; 16 to 17 min: isocratic at 100% B; 17 to 18 min: 100 to 0% B; 18 to 20 min: isocratic at 0% B. The column temperature was 40 °C, the flow rate was 0.5 mL/min, and the injection volume was 4 µL. TF2 and TF3 were solved in water at a concentration of 0.10 mg/mL and 0.25 mg/mL, respectively. Eluted compounds were detected using a Waters PDA detector over a wavelength range of \( \lambda = 200 \) to 800 nm and a Waters QDa mass spectrometer in the positive ion mode with a cone voltage of 15 V and a capillary voltage of 0.8 V. The respective UV chromatograms at 280 nm are displayed in Figs. 3c and 4d. The purity of the alkaloid-enriched fractions (TF2 and TF3) was determined at \( \lambda = 280 \) nm and thereby the concentrations of the alkaloids were calculated.

**5-Bromo-2′-deoxy-uridine incorporation assay and MTT assay**

For determination of DNA synthesis, the BrdU labeling and detection kit III (Roche Diagnostics) was used according to the manufacturer’s instructions based on a method described by Porstmann et al. [19]. The influence of the test compounds on BrdU incorporation was investigated in Hep-G2 (ACC 180), HaCat (ATCC CCL-17), and CaCo-2 cells (ACC 169). After a 24-hour incubation with 1, 10, or 100 µM of the alkaloids in DMEM [high glucose, supplemented with fetal calf serum 10% (Biochrom), nonessential amino acids 1% (Sigma-Aldrich), and penicillin/streptomycin 1% (Biochrom)] at 35°C/5% CO2, 50000–70000 cells/well were transferred into a 96-well plate. Cell viability (≥ 80%) was determined by a CASY cell counter model TT (Roche Innovatis). The number of independent assays was \( n = 3 \) per cell line with 2–3 technical replicates. Cultivation media, supplemented with 10% DMSO, served as a toxicity control.

The MTT assay was performed according to the protocol of Mosmann [32]. The influence of the alkaloids (10, 100, and 300 µM) on MTT turnover was analyzed in human dermal fibroblasts. After culture of the fibroblasts with the test compounds for 24 h and the addition of MTT for 4 h, the formazan was dissolved in DMSO and detected photometrically. The number of independent assays was \( n = 4 \) with 7–8 technical replicates for the untreated samples and the toxicity control (DMSO 10%) and 4 technical replicates for the test compounds.

**Acetylcholinesterase inhibitor assay**

The AChE inhibitor screening kit and the purified AChE of *E. electraca* were obtained from Sigma-Aldrich and used according to the manufacturer’s instructions. All samples contained the same amount of DMSO (1%). The AChE assay is based on the Ellman’s method [33]. The colored product (5-thio-2-nitrobenzoic acid) formed by the active AChE was quantified at \( t_{0 \text{min}} \) and \( t_{10 \text{min}} \) after the addition of the reaction mix by the measurement at \( \lambda = 412 \) nm in a plate reader (CLARIOstar, BMG Labtech). The IC50 values were calculated by fitting sigmoidal dose-response curves with the variable slope using GraphPad Prism version 3.00 for Windows (GraphPad Software).

**Statistics**

All tissue bath experiments were carried out with tracheal slices of at least three different mouse preparations. The results represent the means ± SD. For comparing two different conditions, a two-tailed paired Student’s t-test was performed and for multiple comparisons, ANOVA (analysis of variance) followed by Student-Newman-Keuls post hoc test was performed. In cell assays for multiple comparisons, ANOVA (analysis of variance) followed by Dunnett’s post hoc test was performed. GraphPad Prism Windows version 3.00 (GraphPad Software) was used for analysis. The null hypothesis of each experiment was that the extract, fraction, or substance does not have an influence on the respective parameter. Effects were considered statistically significant if p values were < 0.05.

**Supporting Information**

The extraction and fractionation scheme of lime flower is provided as Supporting Information (Fig. 1S).

**Contributors’ Statement**


**Conflict of Interest**

The authors declare the following competing financial interest: The compounds described here in this study have been recorded for patent application, European Patent Application EP 20193376.9, August 28, 2020.
References


